FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Para fins de pesquisa apenas. Leia o disclaimer completo →

Biblioteca de Peptídeos

Follistatin-344

FS-344 / Follistatin

Growth Factors

Follistatin-344 is a recombinant protein corresponding to the full-length FS344 isoform of human follistatin, a naturally occurring glycoprotein that binds and neutralizes myostatin and other TGF-beta superfamily members including activins. By inhibiting myostatin, it removes the primary negative regulator of skeletal muscle growth, potentially allowing significant muscle hypertrophy. It is a research compound investigated in gene therapy and recombinant protein contexts for muscular dystrophy, age-related sarcopenia, and muscle wasting conditions.

Mecanismo de Ação

Activin-binding protein that potently inhibits myostatin, a negative regulator of muscle growth. Blocking myostatin removes the genetic brake on muscle hypertrophy. Also inhibits FSH (follicle-stimulating hormone) as activin is required for FSH release.

Protocolos de Pesquisa

Para fins de pesquisa apenas. Não é conselhos médicos.

Research protocols use 100-200mcg daily via subcutaneous injection for 10-30 days. Short cycles due to potential FSH suppression. Some protocols use 50mcg daily for extended periods.

Notas de Pesquisa

Clinical Research Status

Follistatin-344 gene therapy (AAV-delivered) has been evaluated in Phase 1/2 clinical trials for inclusion body myositis and Becker muscular dystrophy at Nationwide Children's Hospital. Recombinant protein administration remains purely experimental with no formal clinical trials for the injectable form. The gene therapy approach (delivering the follistatin gene via adeno-associated virus) has shown more clinical progress than exogenous protein administration due to delivery challenges.

Key Published Findings

Animal studies demonstrate that follistatin overexpression produces dramatic muscle hypertrophy (up to 100% increase in muscle mass in mice) by antagonizing myostatin and activin A signaling. Gene therapy trials in humans showed modest improvements in muscle function and walking distance in inclusion body myositis patients. Recombinant follistatin protein has limited bioavailability due to rapid clearance, proteolytic degradation, and challenges in achieving sustained tissue-level concentrations sufficient for myostatin neutralization.

Safety Profile

Gene therapy approaches carry standard AAV-associated risks including immune responses to the viral vector and potential insertional mutagenesis. For recombinant protein, theoretical concerns include effects on reproductive function (activins regulate FSH secretion) and potential tumor promotion through TGF-beta pathway inhibition. No systematic human safety data exists for subcutaneous or intramuscular injection of recombinant follistatin-344 protein outside of gene therapy trials.

Comparison to Related Compounds

Unlike ACE-031 (a soluble activin receptor decoy) which was discontinued due to safety concerns, follistatin is an endogenous protein with a natural role in myostatin regulation. Compared to direct myostatin antibodies (stamulumab/MYO-029), follistatin has broader activity by also neutralizing activins and other TGF-beta ligands. The FS344 isoform is processed into FS315 and FS303 forms with different tissue distributions and binding protein interactions.

Community Observations

The research community notes significant skepticism about the efficacy of subcutaneously injected recombinant follistatin-344 reaching muscle tissue at concentrations sufficient to meaningfully inhibit myostatin. Most experts consider the gene therapy approach far more promising than protein injection for achieving sustained myostatin inhibition. Quality control of commercially available recombinant follistatin is a major concern, as proper protein folding is critical for bioactivity.

Meio-Vivo

~Unknown (protein)

Reconstituição

Bacteriostatic water (BAC)

Armazenamento

Liofilizado

Store at -20C for long term. Refrigerate 2-8C for short term.

Reconstituído

Refrigerate 2-8C. Use within 7 days.

Situação Legal nos EUA

Research chemical (not FDA-approved)

Também Conhecido Como

FS-344Follistatin

Perguntas frequentes

O que é Follistatin-344?

Follistatin-344 is a recombinant protein corresponding to the full-length FS344 isoform of human follistatin, a naturally occurring glycoprotein that binds and neutralizes myostatin and other TGF-beta superfamily members including activins. By inhibiting myostatin, it removes the primary negative regulator of skeletal muscle growth, potentially allowing significant muscle hypertrophy. It is a research compound investigated in gene therapy and recombinant protein contexts for muscular dystrophy, age-related sarcopenia, and muscle wasting conditions.

Como Follistatin-344 funciona?

Activin-binding protein that potently inhibits myostatin, a negative regulator of muscle growth. Blocking myostatin removes the genetic brake on muscle hypertrophy. Also inhibits FSH (follicle-stimulating hormone) as activin is required for FSH release.

Qual é o status regulatório de Follistatin-344 nos EUA?

Research chemical (not FDA-approved)

Qual é a meia-vida de Follistatin-344?

~Unknown (protein)

Por quais outros nomes Follistatin-344 é conhecido?

FS-344, Follistatin

Peptide Contacts fornece resumos baseados em pesquisas apenas para fins informativos. Não hospedamos, distribuímos ou endossamos documentação de fornecedores. Todas as certificações de análise completa, certificados GMP e comunicações de fornecedores devem ser solicitadas e verificadas diretamente pelo comprador. Nada nesta plataforma constitui conselhos legais, médicos ou profissionais. Os usuários são unicamente responsáveis por verificar as credenciais dos fornecedores e garantir a conformidade com todas as leis locais, estaduais e federais aplicáveis antes de adquirir qualquer química de pesquisa. O uso desta plataforma constitui aceitação plena da responsabilidade pessoal.

Leia a declaração completa